Mesonephric adenocarcinoma of the uterine cervix with a prominent spindle cell component

Fan,Yingying; He,Ying; Sun,Liang; Liu,Tianmin; Shen,Yangmei

doi:10.3892/ol.2024.14641

Mesonephric adenocarcinoma of the uterine cervix with a prominent spindle cell component

Authors:
- Yingying Fan
- Ying He
- Liang Sun
- Tianmin Liu
- Yangmei Shen
View Affiliations

Affiliations: Department of Pathology, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610011, P.R. China
Published online on: August 22, 2024 https://doi.org/10.3892/ol.2024.14641
Article Number: 508
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesonephric adenocarcinomas (MAs) with spindle cell components are rare malignant cervical tumours. In the present study, a retrospective analysis of these tumours was performed. Clinicopathological data were gathered from electronic surgical pathology records, and both immunohistochemistry and targeted next‑generation sequencing (NGS) were performed. The present study included three postmenopausal female patients diagnosed with primary uterine cervical MA with prominent spindle cell components, aged 51‑60 years. All patients underwent hysterectomy with bilateral salpingo‑oophorectomy and pelvic lymph node dissection. There were no recurrences or deaths after surgery. NGS analysis identified KRAS mutations in 2 cases and a PIK3‑catalytic subunit α (PIK3CA) mutation in another. Spindle cell components may indicate MAs at an advanced stage. Spindle cell components in MAs are diagnostic pitfalls, and the use of immunohistochemical panels and molecular detection cases with overlapping morphological features is recommended. While KRAS mutations are the most common types of mutations in MAs with spindle cell components, the present study demonstrates that PIK3CA mutations can also occur independently in cases without KRAS mutations.

View Figures

View References

1	Sajjad Y: Development of the genital ducts and external genitalia in the early human embryo. J Obstet Gynaecol Res. 36:929–937. 2010. View Article : Google Scholar : PubMed/NCBI
2	Howitt BE and Nucci MR: Mesonephric proliferations of the female genital tract. Pathology. 50:141–150. 2018. View Article : Google Scholar : PubMed/NCBI
3	Mirkovic J, Sholl LM, Garcia E, Lindeman N, MacConaill L, Hirsch M, Dal Cin P, Gorman M, Barletta JA, Nucci MR, et al: Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Mod Pathol. 28:1504–1514. 2015. View Article : Google Scholar : PubMed/NCBI
4	Montalvo N, Redroban L and Galarza D: Mesonephric adenocarcinoma of the cervix: A case report with a three-year follow-up, lung metastases, and next-generation sequencing analysis. Diagn Pathol. 14:712019. View Article : Google Scholar : PubMed/NCBI
5	Menon S, Kathuria K, Deodhar K and Kerkar R: Mesonephric adenocarcinoma (endometrioid type) of endocervix with diffuse mesonephric hyperplasia involving cervical wall and myometrium: An unusual case report. Indian J Pathol Microbiol. 56:51–53. 2013. View Article : Google Scholar : PubMed/NCBI
6	da Silva EM, Fix DJ, Sebastiao APM, Selenica P, Ferrando L, Kim SH, Stylianou A, Da Cruz Paula A, Pareja F, Smith ES, et al: Mesonephric and mesonephric-like carcinomas of the female genital tract: Molecular characterization including cases with mixed histology and matched metastases. Mod Pathol. 34:1570–1587. 2021. View Article : Google Scholar : PubMed/NCBI
7	Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, et al: Targeted genomic profiling reveals recurrent kras mutations in mesonephric-like adenocarcinomas of the female genital tract. Am J Surg Pathol. 42:227–233. 2018. View Article : Google Scholar : PubMed/NCBI
8	Dierickx A, Goker M, Braems G, Tummers P and Van den Broecke R: Mesonephric adenocarcinoma of the cervix: Case report and literature review. Gynecol Oncol Rep. 17:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pors J, Segura S, Chiu DS, Almadani N, Ren H, Fix DJ, Howitt BE, Kolin D, McCluggage WG, Mirkovic J, et al: Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: A multi-institutional study. Am J Surg Pathol. 45:498–506. 2021. View Article : Google Scholar : PubMed/NCBI
10	Bhatla N, Berek JS, Fredes MC, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, et al: Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 145:129–135. 2019. View Article : Google Scholar : PubMed/NCBI
11	Klinkhamer PJ, Meerding WJ, Rosier PF and Hanselaar AG: Liquid-based cervical cytology. Cancer. 99:263–271. 2003. View Article : Google Scholar : PubMed/NCBI
12	Devarashetty S, Chennapragada SS and Mansour R: Not your typical adenocarcinoma: A case of mesonephric adenocarcinoma of the cervix with fibroblast growth factor receptor 2 (FGFR2) mutation. Cureus. 14:e250982022.PubMed/NCBI
13	Jiang LL, Tong DM, Feng ZY and Liu KR: Mesonephric adenocarcinoma of the uterine cervix with rare lung metastases: A case report and review of the literature. World J Clin Cases. 8:1735–1744. 2020. View Article : Google Scholar : PubMed/NCBI
14	Tseng CE, Chen CH, Chen SJ and Chi CL: Tumor rupture as an initial manifestation of malignant mesonephric mixed tumor: A case report and review of the literature. Int J Clin Exp Pathol. 7:1212–1217. 2014.PubMed/NCBI
15	Ribeiro B, Silva R, Dias R and Patrício V: Carcinosarcoma of the uterine cervix: A rare pathological finding originating from mesonephric remnants. BMJ Case Rep. 12:e2270502019. View Article : Google Scholar : PubMed/NCBI
16	Fregnani JH, Soares FA, Novik PR, Lopes A and Latorre MR: Comparison of biological behavior between early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. Eur J Obstet Gynecol Reprod Biol. 136:215–223. 2008. View Article : Google Scholar : PubMed/NCBI
17	Jeong JH, Kim NY and Pyo JS: Analysis of PAX8 immunohistochemistry in lung cancers: A meta-analysis. J Pathol Transl Med. 54:300–309. 2020. View Article : Google Scholar : PubMed/NCBI
18	Kenny SL, McBride HA, Jamison J and McCluggage WG: Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-β. Am J Surg Pathol. 36:799–807. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kadota K, Buitrago D, Lee MC, Villena-Vargas J, Sima CS, Jones DR, Travis WD and Adusumilli PS: Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer. 89:329–336. 2015. View Article : Google Scholar : PubMed/NCBI
20	Howitt BE, Emori MM, Drapkin R, Gaspar C, Barletta JA, Nucci MR, McCluggage WG, Oliva E and Hirsch MS: GATA3 is a sensitive and specific marker of benign and malignant mesonephric lesions in the lower female genital tract. Am J Surg Pathol. 39:1411–1419. 2015. View Article : Google Scholar : PubMed/NCBI
21	Pors J, Cheng A, Leo JM, Kinloch MA, Gilks B and Hoang L: A comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract. Am J Surg Pathol. 42:1596–1606. 2018. View Article : Google Scholar : PubMed/NCBI
22	Lee Y, Bae H and Kim HS: Endocervical adenocarcinoma: Comprehensive histological review and re-classification of 123 consecutive cases according to the updated world health organization classification of female genital tumors. Anticancer Res. 42:4627–4639. 2022. View Article : Google Scholar : PubMed/NCBI
23	Masjeed NMA, Khandeparkar SGS, Joshi AR, Kulkarni MM and Pandya N: Immunohistochemical study of ER, PR, Ki67 and p53 in endometrial hyperplasias and endometrial carcinomas. J Clin Diagn Res. 11:EC31–EC34. 2017.PubMed/NCBI
24	Meguro S, Yasuda M, Shimizu M, Kurosaki A and Fujiwara K: Mesonephric adenocarcinoma with a sarcomatous component, a notable subtype of cervical carcinosarcoma: A case report and review of the literature. Diagn Pathol. 8:742013. View Article : Google Scholar : PubMed/NCBI
25	Bague S, Rodriguez IM and Prat J: Malignant mesonephric tumors of the female genital tract: A clinicopathologic study of 9 cases. Am J Surg Pathol. 28:601–607. 2004. View Article : Google Scholar : PubMed/NCBI
26	Silver SA, Devouassoux-Shisheboran M, Mezzetti TP and Tavassoli FA: Mesonephric adenocarcinomas of the uterine cervix: A study of 11 cases with immunohistochemical findings. Am J Surg Pathol. 25:379–387. 2001. View Article : Google Scholar : PubMed/NCBI
27	Mirkovic J, Olkhov-Mitsel E, Amemiya Y, Al-Hussaini M, Nofech-Mozes S, Djordjevic B, Kupets R, Seth A and McCluggage WG: Mesonephric-like adenocarcinoma of the female genital tract: Novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas. Histopathology. 82:978–990. 2023. View Article : Google Scholar : PubMed/NCBI
28	McCluggage WG: Mesonephric-like Adenocarcinoma of the female genital tract: From Morphologic observations to a well-characterized carcinoma with aggressive clinical behavior. Adv Anat Pathol. 29:208–216. 2022. View Article : Google Scholar : PubMed/NCBI
29	Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK and Matsuo K: Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 160:586–601. 2021. View Article : Google Scholar : PubMed/NCBI
30	Kuburich NA, den Hollander P, Pietz JT and Mani SA: Vimentin and cytokeratin: Good alone, bad together. Semin Cancer Biol. 86:816–826. 2022. View Article : Google Scholar : PubMed/NCBI
31	Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar : PubMed/NCBI
32	Xi Q, Kage H, Ogawa M, Matsunaga A, Nishijima A, Sone K, Kawana K and Oda K: Genomic landscape of endometrial, ovarian, and cervical cancers in Japan from the database in the center for cancer genomics and advanced therapeutics. Cancers (Basel). 16:1362023. View Article : Google Scholar : PubMed/NCBI
33	Mirkovic J, Schoolmeester JK, Campbell F, Miron A, Nucci MR and Howitt BE: Cervical mesonephric hyperplasia lacks KRAS/NRAS mutations. Histopathology. 71:1003–1005. 2017. View Article : Google Scholar : PubMed/NCBI
34	Cancer Genome Atlas Research Network, . Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
35	Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, et al: PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Sci Rep. 7:102402017. View Article : Google Scholar : PubMed/NCBI
36	McIntyre JB, Wu JS, Craighead PS, Phan T, Köbel M, Lees-Miller SP, Ghatage P, Magliocco AM and Doll CM: PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 128:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
37	Wang Y, He M, He T, Ouyang X, Shen X, Shi W, Huang S, Xiang L, Zou D, Jiang W and Yang H: Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers. Br J Cancer. 130:987–1000. 2024. View Article : Google Scholar : PubMed/NCBI
38	Olson JM and Hallahan AR: p38 MAP kinase: A convergence point in cancer therapy. Trends Mol Med. 10:125–129. 2004. View Article : Google Scholar : PubMed/NCBI
39	Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
40	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
41	Cocco E, Scaltriti M and Drilon A: NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 15:731–747. 2018. View Article : Google Scholar : PubMed/NCBI
42	Pasini L, Re A, Tebaldi T, Ricci G, Boi S, Adami V, Barbareschi M and Quattrone A: TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines. BMC Cancer. 15:7772015. View Article : Google Scholar : PubMed/NCBI
43	Xie C, Chen Q and Shen Y: Mesonephric adenocarcinomas in female genital tract: A case series. Medicine (Baltimore). 100:e271742021. View Article : Google Scholar : PubMed/NCBI
44	Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, et al: Adagrasib in non-small-cell lung cancer harboring a KRAS^G12C mutation. N Engl J Med. 387:120–131. 2022. View Article : Google Scholar : PubMed/NCBI
45	Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, et al: Identification of MRTX1133, a noncovalent, potent, and selective KRAS^G12D inhibitor. J Med Chem. 65:3123–3133. 2022. View Article : Google Scholar : PubMed/NCBI
46	Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, et al: Anti-tumor efficacy of a potent and selective non-covalent KRAS^G12D inhibitor. Nat Med. 28:2171–2182. 2022. View Article : Google Scholar : PubMed/NCBI
47	Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, et al: Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: Results from the first-in-human study. J Clin Oncol. 36:1291–1299. 2018. View Article : Google Scholar : PubMed/NCBI